For Puma Biotechnology Inc. [PBYI], BofA/Merrill sees a rise to $9. What next?

Puma Biotechnology Inc. [NASDAQ: PBYI] closed the trading session at $10.38 on 08/06/20. The day’s price range saw the stock hit a low of $10.26, while the highest price level was $10.86. The company report on August 6, 2020 that Puma Biotechnology Reports Second Quarter 2020 Financial Results.

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2020. Unless otherwise stated, all comparisons are for the second quarter of 2020 compared to the second quarter of 2019.

Product revenue, net consists entirely of sales revenue from NERLYNX®, Puma’s first commercial product. Net NERLYNX product revenue in the second quarter of 2020 was $48.8 million, compared to $53.8 million in the second quarter of 2019. Net NERLYNX product revenue in the first six months of 2020 was $97.4 million, compared to $99.4 million in the first six months of 2019.

The stocks have a year to date performance of 18.63 percent and weekly performance of -1.14 percent. The stock has been moved at -23.17 percent over the last six months. The stock has performed 1.47 percent around the most recent 30 days and changed 5.06 percent over the most recent 3-months.

If compared to the average trading volume of 1.07M shares, PBYI reached to a volume of 1451235 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Puma Biotechnology Inc. [PBYI]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PBYI shares is $12.11 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PBYI stock is a recommendation set at 3.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

BofA/Merrill have made an estimate for Puma Biotechnology Inc. shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on June 25, 2020. While these analysts kept the previous recommendation, Goldman raised their target price from $24 to $8. The new note on the price target was released on October 08, 2019, representing the official price target for Puma Biotechnology Inc. stock. Previously, the target price had yet another raise to $24, while Citigroup analysts kept a Neutral rating on PBYI stock. On May 10, 2019, analysts decreased their price target for PBYI shares from 57 to 20.

The Average True Range (ATR) for Puma Biotechnology Inc. is set at 0.64, with the Price to Sales ratio for PBYI stock in the period of the last 12 months amounting to 1.85. The Price to Book ratio for the last quarter was 43.25, with the Price to Cash per share for the same quarter was set at 2.51.

PBYI stock trade performance evaluation

Puma Biotechnology Inc. [PBYI] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.14. With this latest performance, PBYI shares gained by 1.47% in over the last four-week period, additionally sinking by -23.17% over the last 6 months – not to mention a rise of 17.82% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PBYI stock in for the last two-week period is set at 49.14, with the RSI for the last a single of trading hit 49.92, and the three-weeks RSI is set at 49.86 for Puma Biotechnology Inc. [PBYI]. The present Moving Average for the last 50 days of trading for this stock 10.42, while it was recorded at 10.65 for the last single week of trading, and 9.66 for the last 200 days.

Puma Biotechnology Inc. [PBYI]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Puma Biotechnology Inc. [PBYI] shares currently have an operating margin of -14.36 and a Gross Margin at +86.48. Puma Biotechnology Inc.’s Net Margin is presently recorded at -27.77.

Return on Total Capital for PBYI is now -24.14, given the latest momentum, and Return on Invested Capital for the company is -47.06. Return on Equity for this stock declined to -292.05, with Return on Assets sitting at -30.60. When it comes to the capital structure of this company, Puma Biotechnology Inc. [PBYI] has a Total Debt to Total Equity ratio set at 688.48. Additionally, PBYI Total Debt to Total Capital is recorded at 87.32, with Total Debt to Total Assets ending up at 51.18. Long-Term Debt to Equity for the company is recorded at 673.45, with the Long-Term Debt to Total Capital now at 85.41.

Reflecting on the efficiency of the workforce at the company, Puma Biotechnology Inc. [PBYI] managed to generate an average of -$281,022 per employee. Receivables Turnover for the company is 10.71 with a Total Asset Turnover recorded at a value of 1.10.Puma Biotechnology Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.70 and a Current Ratio set at 1.80.

Earnings per share (EPS) analysis for Puma Biotechnology Inc. [PBYI] stock

With the latest financial reports released by the company, Puma Biotechnology Inc. posted -0.44/share EPS, while the average EPS was predicted by analysts to be reported at -0.71/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 38.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PBYI.

Puma Biotechnology Inc. [PBYI]: Insider Ownership positions

There are presently around $407 million, or 97.50% of PBYI stock, in the hands of institutional investors. The top three institutional holders of PBYI stocks are: FRED ALGER MANAGEMENT, LLC with ownership of 4,669,934, which is approximately 163.662% of the company’s market cap and around 12.00% of the total institutional ownership; VANGUARD GROUP INC, holding 4,634,697 shares of the stock with an approximate value of $48.11 million in PBYI stocks shares; and STATE STREET CORP, currently with $36.74 million in PBYI stock with ownership of nearly 0.926% of the company’s market capitalization.

61 institutional holders increased their position in Puma Biotechnology Inc. [NASDAQ:PBYI] by around 12,654,215 shares. Additionally, 68 investors decreased positions by around 5,021,370 shares, while 22 investors held positions by with 21,523,635 shares. The mentioned changes placed institutional holdings at 39,199,220 shares, according to the latest SEC report filing. PBYI stock had 18 new institutional investments in for a total of 5,745,693 shares, while 26 institutional investors sold positions of 1,517,655 shares during the same period.

Share on facebook
Share on twitter
Share on linkedin
Share on skype
Share on reddit

Leave a Comment

Your email address will not be published. Required fields are marked *



Download Free eBook For


100% free. stop anytime no spam



Download Free eBook For


100% free. stop anytime no spam